Evaluation of antiviral effects and toxicity of herbal medicine Vipdervir capsules
Pharmacognosy Journal
; 14(3):681-689, 2022.
Article
in English
| CAB Abstracts | ID: covidwho-2283973
ABSTRACT
Background:
Antiviral vaccine is not effective, synthetic antiviral drugs are highly toxic, leading to increased interest in herbal medicines as promising antiviral drugs. Recently, Vipdervir has been developed from medicinal herbs with the aim to support and treat diseases caused by viruses such as H5N1 and SARSCoV- 2. In the present study, we assessed Vipdervir's antiviral activity against H5N1 and SARS-CoV-2. In addition, we also evaluated the acute toxicity and repeated dose toxicity of Vipdervir in mice and rabbits, respectively.Methods:
H5N1 inhibitory effect of Vipdervir was assessed using hemagglutination inhibition assay. Vipdervir's SARS-CoV-2 inhibitory effect was evaluated by Plaque Reduction Neutralization assay. Acute and repeated dose oral toxicities of Vipdervir were determined according to OECD 423 and OECD 407 guidelines, respectively.Results:
Data show that Vipdervir is effective against both H5N1 and SARSCoV- 2. At concentrations of 3 mg/mL and 5 mg/mL Vipdervir completely inhibits H5N1. At a concentration of 50 g/mL Vipdervir showed an inhibitory effect on SARS-CoV-2. Acute toxicity data revealed that the LD50 of Vipdervir is greater than 35200 mg/kg, b.wt. in mice. Repeated toxicity data indicated that Vipdervir did not induce significant differences in body weight gain, hematology and clinical biochemistry in compared to the control group. The No Observed Adverse Effect Level of Vipdervir is greater than 613.8 mg/kg b.wt./day in rabbits. No delayed toxicity effects of Vipdervir were observed.Conclusion:
Vipdervir capsules were found to be antiviral effective and relatively safe in the tested doses and experimental conditions.
Animal and in vitro Models for Pharmaceuticals [VV450], Non-food/Non-feed Plant Products [SS200], Prion; Viral; Bacterial and Fungal Pathogens of Humans [VV210], Pesticides and Drugs, Control [HH405], toxicity, animal models, antiviral properties, herbal drugs, viral diseases, coronavirus disease 2019, human diseases, fruits, roots, rhizomes, medicinal plants, plant extracts, mice, rabbits, Severe acute respiratory syndrome coronavirus 2, man, Andrographis, Bupleurum, Artemisia annua, Houttuynia cordata, Zingiber, Glycyrrhiza, Styphnolobium japonicum, Silybum, Scutellaria, plants, Muridae, rodents, mammals, vertebrates, Chordata, animals, eukaryotes, Leporidae, Lagomorpha, Severe acute respiratory syndrome-related coronavirus, Betacoronavirus, Coronavirinae, Coronaviridae, Nidovirales, positive-sense ssRNA Viruses, ssRNA Viruses, RNA Viruses, viruses, Homo, Hominidae, primates, Acanthaceae, Lamiales, eudicots, angiosperms, Spermatophyta, Apiaceae, Apiales, Artemisia, Asteraceae, Asterales, Houttuynia (Spermatophyta), Saururaceae, Piperales, magnoliids, Zingiberaceae, Zingiberales, commelinids, monocotyledons, Papilionoideae, Fabaceae, Fabales, Styphnolobium, Lamiaceae, anti-viral properties, herbal medicines, SARS-CoV-2, viral infections, drug plants, medicinal herbs, officinal plants
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Type of study:
Experimental Studies
Topics:
Traditional medicine
Language:
English
Journal:
Pharmacognosy Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS